Trevena (NASDAQ: TRVN)
Trevena Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Trevena Company Info
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
News & Analysis
2 Best Reddit Healthcare Stocks to Buy Now
These high-risk, high-reward healthcare stocks have outperformed the market over the past year.
Here's the Best Healthcare Stock on Robinhood to Buy Now
This is the story of an emerging healthcare company on its way to capturing a billion-dollar market opportunity.
Why Shares of Trevena Blasted Nearly 17% Higher on Monday
An analyst initiates coverage on the stock with an unequivocal buy recommendation.
Why Trevena Stock Is Plunging Today
The biopharmaceutical company announced the pricing of a public offering of common stock.
Why Trevena Stock Surged Today
The biotech's innovative painkiller is the first new drug in its class in decades.
Here's Why Trevena Dropped 11.8% Today
The company reported fourth-quarter and full-year 2016 earnings.
3 Tempting Stocks to Avoid
These three stocks are better left alone.
Here's Why Trevena Shares Dropped as Much as 36% Tuesday Morning
The company's lead drug met its primary endpoints, but investors are worried about lacking data elsewhere.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.